- Home
- OSUR vs OTLK Comparison
OSUR vs OTLK Comparison
Compare OSUR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OSUR | OTLK |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.4M | 249.6M |
| IPO Year | 2000 | 2016 |
Fundamental Metrics
Financial Performance| Metric | OSUR | OTLK |
|---|---|---|
| Price | $4.35 | $1.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $3.00 | $2.50 |
| AVG Volume (30 Days) | 670.4K | ★ 15.2M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $167,064,000.00 | $8,146,123.00 |
| Revenue This Year | $4.48 | $1,430.98 |
| Revenue Next Year | $7.76 | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.08 | $0.16 |
| 52 Week High | $4.58 | $3.39 |
Technical Indicators
Market Signals| Indicator | OSUR | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 58.92 | 59.67 |
| Support Level | $2.84 | $0.26 |
| Resistance Level | $4.58 | $1.54 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 59.65 | 42.11 |
Price Performance
Historical ComparisonAbout OSUR OraSure Technologies Inc.
OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.